Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Vertex Pharmaceuticals Incorporated (VRTX) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 9:00 AM ET Company Participants Reshma Kewalramani - President and CEO Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay Good morning, and thank you for joining Guggenheim's Inaugural Healthcare Innovations Conference. I am Debjit, one of the therapeutic analysts, and my privilege to welcome Dr. Reshma Kewalramani, President and CEO of Vertex.
Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity
Regulators are reviewing what could become a multi-billion-dollar drug.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vertex Pharmaceuticals (VRTX) Just Overtook the 20-Day Moving Average
Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average, which suggests a short-term bullish trend.
Vertex Pharmaceuticals (VRTX) Crossed Above the 50-Day Moving Average: What That Means for Investors
From a technical perspective, Vertex Pharmaceuticals (VRTX) is looking like an interesting pick, as it just reached a key level of support. VRTX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
Vertex (VRTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Vertex (VRTX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised
Vertex's third-quarter 2024 earnings and revenues beat estimates. The company raises its full-year product revenue guidance.
Vertex Pharmaceuticals Incorporated (VRTX) Q3 2024 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Dr. Reshma Kewalramani - President and CEO Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer Conference Call Participants Jessica Fye - J.P. Morgan Salveen Richter - Goldman Sachs Chris Garcia - Morgan Stanley Mohit Bansal - Wells Fargo Tazeen Ahmad - Bank of America Michael Yee - Jefferies Evan Seigerman - BMO Capital Markets Phil Nadeau - TD Cowen Debjit Chattopadhyay - Guggenheim Partners Olivia Brayer - Cantor Fitzgerald Liisa Bayko - Evercore ISI Operator Good day.
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.38 per share, beating the Zacks Consensus Estimate of $4.13 per share. This compares to earnings of $4.08 per share a year ago.
Prediction: Vertex Pharmaceuticals (VRTX) Could Be The Next Stock Split Stock
Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their shares into smaller slices.
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $475.08, representing a +1% change from its previous close.
